Spain Advances Vanguard Health Plan with Major Investments and New Biotech Initiatives

The Government in Spain has already executed 82% of the 2.48 billion euros of public investment and 56% of the 363 million euros of private investment of the Strategic Project for Economic Recovery and Transformation (Perte) for Cutting-Edge Health. The plan seeks to make the healthcare system in Spain more innovative, connected, and people-centered.

“We are consolidating a more innovative, connected, and people-centered healthcare system,” said Mónica García, Minister of Health, who emphasized that the Vanguard Health Program in Spain has three strategic lines based on promoting personalized precision medicine, the digital transformation of healthcare, and advanced training for professionals.

This was his statement during the fifth meeting of this project, after which he emphasized that these investments “not only modernize the capacity of the National Health System (NHS), but also prepare it to face future challenges with greater equity, efficiency, and resilience.”

The Minister of Science, Innovation, and Universities, Diana Morant, stated that the Vanguard Health Plan in Spain seeks to improve the current and future health of both Spanish society and the economy. “It is a success story both in its implementation and in its transformative capacity and connection between public and private stakeholders, as well as the various administrations, including the autonomous communities,” she added.

It’s worth noting that the Vanguard Health Plan in Spain encompasses 60 different initiatives coordinated across five ministries

The most notable is the launch of Terafront, the country’s first public-private partnership for advanced therapies. This partnership, with an initial investment of €37 million in public capital and €38 million in private capital, aims to accelerate the availability of cutting-edge therapies through the NHS.

Likewise, progress is being made in the creation of the pioneering National Neurotechnology Center, Spain Neurotech , to develop technological tools based on the fundamentals of the human brain. This project will receive €40 million from the Recovery, Transformation and Resilience Plan (PRTR) and a further €80 million from the General State Budget (PGE).

The Vanguard Health Perte has 60 different actions coordinated between five ministries
Another of this Perte’s achievements is the creation of the world’s first personal pediatric exoskeleton, developed by the company MARSI-Bionics , a spinoff of the Spanish National Research Council (CSIC).

The meeting also announced that Spain will participate in the European Project of Common Interest in Health (Ipcei-Medcure) Call, with the aim of improving research and development of industrial health capacities in Europe through the development of new drugs, better models to identify and test therapies, the creation of new pharmacological substances and innovative vaccines , and the creation of innovative production processes towards sustainability in the health value chain.

To this end, up to €127 million will be allocated to six Spanish companies through the Center for Technological Development and Innovation (CDTI). Since the last meeting, initiatives have been implemented, such as the 2024 Independent Clinical Research Call of the Carlos III Health Institute (ISCIII) and TransMisiones, a joint call between the CDTI and the State Research Agency (AEI) to combat antimicrobial resistance.

__

(Featured image by Layla Ortega Fernandez via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us